1. Charting Progress in MS Diagnosis and Treatment for Today and Tomorrow

3. Disclaimer

4. Program Goals

5. Overview

6. Charting Progress in Diagnosis: Revised Diagnostic Criteria - 2010

7. Revised Diagnostic Criteria - 2010 (cont)

8. Applying the Revised Criteria

9. Applying the Revised Criteria (cont): Dissemination in Time

10. Applying the Revised Criteria (cont): Dissemination in Space

11. Applying the Revised Criteria (cont): RIS

12. Charting Progress in Treatment of MS

13. Choosing Treatment

14. Comorbidities and Considerations: Some Examples

15. Older Drugs, Newer Data: Glatiramer Acetate

16. Older Drugs, Newer Data: Generic Formulations

17. JC Virus Antibody Index

18. PEGylated Interferon

19. Oral MS Drugs as First-line Therapy

20. Approaches to MRI Monitoring

21. Approaches to Lab Monitoring

22. Switching MS Therapy

23. Disease Activity-Free Status: A New Paradigm?

24. MS Drug Pipeline: Monoclonal Antibodies

25. Biomarkers

26. Abbreviations

27. References

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)